Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$58.6 million.

  • Protagonist Therapeutics' Cash from Investing Activities rose 7194.43% to -$58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.9 million, marking a year-over-year increase of 6964.25%. This contributed to the annual value of -$299.5 million for FY2024, which is 66285.85% down from last year.
  • Protagonist Therapeutics' Cash from Investing Activities amounted to -$58.6 million in Q3 2025, which was up 7194.43% from $54.8 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Cash from Investing Activities high stood at $57.3 million for Q3 2022, and its period low was -$208.7 million during Q3 2024.
  • For the 5-year period, Protagonist Therapeutics' Cash from Investing Activities averaged around -$19.0 million, with its median value being -$4.5 million (2022).
  • In the last 5 years, Protagonist Therapeutics' Cash from Investing Activities soared by 34685.45% in 2022 and then crashed by 165748.41% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Cash from Investing Activities (Quarter) stood at $27.9 million in 2021, then plummeted by 85.88% to $3.9 million in 2022, then crashed by 1657.48% to -$61.3 million in 2023, then skyrocketed by 85.76% to -$8.7 million in 2024, then plummeted by 571.12% to -$58.6 million in 2025.
  • Its Cash from Investing Activities stands at -$58.6 million for Q3 2025, versus $54.8 million for Q2 2025 and -$94.4 million for Q1 2025.